Novel anthra[1,2-c][1,2,5]thiadiazole-6,11-diones as promising anticancer lead compounds: Biological evaluation, characterization & molecular targets determination

Ahmed Atef Ahmed Ali, Yu Ru Lee, Tsung Chih Chen, Chun Liang Chen, Chia Chung Lee, Chia Yang Shiau, Chiao Hsi Chiang, Hsu Shan Huang

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The novel compounds NSC745885 and NSC757963 developed at our laboratory were tested against a panel of 60 cancer cell lines at the National Cancer Institute, USA, and a panel of 39 cancer cell lines at the Japanese Foundation of Cancer Research. Both compounds demonstrated selective unique multi-log differential patterns of activity, with GI50 values in the sub-micro molar range against cancer cells rather than normal cardiac cells. NSC757963 showed high selectivity towards the leukemia subpanel. Activities of both compounds strongly correlated to expression of NFKB1 and CSNK2B genes, implying that they may inhibit the NF-κB pathway. Immunocytochemical microscopy of OVCAR-3 cells showed clear cytosolic accumulation of the NF-κB p65 subunit following treatment. Western blotting showed dose dependent inhibition of the nuclear expression of the NF-κB p65 subunit with subsequent accumulation in the cytosol following treatment. Docking experiments showed binding of both compounds to the NF-κB activator IKKβ subunit preventing its translocation to the nucleus. Collectively, these results confirm the ability of our compounds to inhibit the constitutively active NF-κB pathway of OVCAR-3 cells. Furthermore, COMPARE analysis indicated that the activity of NSC757963 is similar to the antituberculosis agent rifamycin SV, this was confirmed by testing the antimycobacterial activity of NSC757963 against Mycobacterium tuberculosis, results revealed potent activity suitable for use in clinical practice. Molecular properties and Lipinski's parameters predicted acceptable bioavailability properties with no indication of mutagenicity, tumorigenicity, irritability and reproductive effects. Oral absorption experiments using the human Caco-2 model showed high intestinal absorption of NSC745885 by passive transport mechanism with no intestinal efflux or active transport mechanisms. The unique molecular characterization as well as the illustrated anticancer spectra of activity and bioavailability properties warrant further development of our compounds and present a foundation brick in the pre-clinical investigations to implement such compounds in clinical practice.

Original languageEnglish
Article numbere0154278
JournalPLoS One
Volume11
Issue number4
DOIs
Publication statusPublished - Apr 1 2016

Fingerprint

biochemical compounds
Lead compounds
Cells
bioavailability
rifamycins
cell lines
Biological Availability
Neoplasms
bricks
neoplasms
active transport
mutagenicity
intestinal absorption
Mycobacterium tuberculosis
cells
Brick
leukemia
cytosol
Cell Line
National Cancer Institute (U.S.)

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Novel anthra[1,2-c][1,2,5]thiadiazole-6,11-diones as promising anticancer lead compounds : Biological evaluation, characterization & molecular targets determination. / Ali, Ahmed Atef Ahmed; Lee, Yu Ru; Chen, Tsung Chih; Chen, Chun Liang; Lee, Chia Chung; Shiau, Chia Yang; Chiang, Chiao Hsi; Huang, Hsu Shan.

In: PLoS One, Vol. 11, No. 4, e0154278, 01.04.2016.

Research output: Contribution to journalArticle

Ali, Ahmed Atef Ahmed ; Lee, Yu Ru ; Chen, Tsung Chih ; Chen, Chun Liang ; Lee, Chia Chung ; Shiau, Chia Yang ; Chiang, Chiao Hsi ; Huang, Hsu Shan. / Novel anthra[1,2-c][1,2,5]thiadiazole-6,11-diones as promising anticancer lead compounds : Biological evaluation, characterization & molecular targets determination. In: PLoS One. 2016 ; Vol. 11, No. 4.
@article{9aad3d8877e9407787368e8735c6ece5,
title = "Novel anthra[1,2-c][1,2,5]thiadiazole-6,11-diones as promising anticancer lead compounds: Biological evaluation, characterization & molecular targets determination",
abstract = "The novel compounds NSC745885 and NSC757963 developed at our laboratory were tested against a panel of 60 cancer cell lines at the National Cancer Institute, USA, and a panel of 39 cancer cell lines at the Japanese Foundation of Cancer Research. Both compounds demonstrated selective unique multi-log differential patterns of activity, with GI50 values in the sub-micro molar range against cancer cells rather than normal cardiac cells. NSC757963 showed high selectivity towards the leukemia subpanel. Activities of both compounds strongly correlated to expression of NFKB1 and CSNK2B genes, implying that they may inhibit the NF-κB pathway. Immunocytochemical microscopy of OVCAR-3 cells showed clear cytosolic accumulation of the NF-κB p65 subunit following treatment. Western blotting showed dose dependent inhibition of the nuclear expression of the NF-κB p65 subunit with subsequent accumulation in the cytosol following treatment. Docking experiments showed binding of both compounds to the NF-κB activator IKKβ subunit preventing its translocation to the nucleus. Collectively, these results confirm the ability of our compounds to inhibit the constitutively active NF-κB pathway of OVCAR-3 cells. Furthermore, COMPARE analysis indicated that the activity of NSC757963 is similar to the antituberculosis agent rifamycin SV, this was confirmed by testing the antimycobacterial activity of NSC757963 against Mycobacterium tuberculosis, results revealed potent activity suitable for use in clinical practice. Molecular properties and Lipinski's parameters predicted acceptable bioavailability properties with no indication of mutagenicity, tumorigenicity, irritability and reproductive effects. Oral absorption experiments using the human Caco-2 model showed high intestinal absorption of NSC745885 by passive transport mechanism with no intestinal efflux or active transport mechanisms. The unique molecular characterization as well as the illustrated anticancer spectra of activity and bioavailability properties warrant further development of our compounds and present a foundation brick in the pre-clinical investigations to implement such compounds in clinical practice.",
author = "Ali, {Ahmed Atef Ahmed} and Lee, {Yu Ru} and Chen, {Tsung Chih} and Chen, {Chun Liang} and Lee, {Chia Chung} and Shiau, {Chia Yang} and Chiang, {Chiao Hsi} and Huang, {Hsu Shan}",
year = "2016",
month = "4",
day = "1",
doi = "10.1371/journal.pone.0154278",
language = "English",
volume = "11",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "4",

}

TY - JOUR

T1 - Novel anthra[1,2-c][1,2,5]thiadiazole-6,11-diones as promising anticancer lead compounds

T2 - Biological evaluation, characterization & molecular targets determination

AU - Ali, Ahmed Atef Ahmed

AU - Lee, Yu Ru

AU - Chen, Tsung Chih

AU - Chen, Chun Liang

AU - Lee, Chia Chung

AU - Shiau, Chia Yang

AU - Chiang, Chiao Hsi

AU - Huang, Hsu Shan

PY - 2016/4/1

Y1 - 2016/4/1

N2 - The novel compounds NSC745885 and NSC757963 developed at our laboratory were tested against a panel of 60 cancer cell lines at the National Cancer Institute, USA, and a panel of 39 cancer cell lines at the Japanese Foundation of Cancer Research. Both compounds demonstrated selective unique multi-log differential patterns of activity, with GI50 values in the sub-micro molar range against cancer cells rather than normal cardiac cells. NSC757963 showed high selectivity towards the leukemia subpanel. Activities of both compounds strongly correlated to expression of NFKB1 and CSNK2B genes, implying that they may inhibit the NF-κB pathway. Immunocytochemical microscopy of OVCAR-3 cells showed clear cytosolic accumulation of the NF-κB p65 subunit following treatment. Western blotting showed dose dependent inhibition of the nuclear expression of the NF-κB p65 subunit with subsequent accumulation in the cytosol following treatment. Docking experiments showed binding of both compounds to the NF-κB activator IKKβ subunit preventing its translocation to the nucleus. Collectively, these results confirm the ability of our compounds to inhibit the constitutively active NF-κB pathway of OVCAR-3 cells. Furthermore, COMPARE analysis indicated that the activity of NSC757963 is similar to the antituberculosis agent rifamycin SV, this was confirmed by testing the antimycobacterial activity of NSC757963 against Mycobacterium tuberculosis, results revealed potent activity suitable for use in clinical practice. Molecular properties and Lipinski's parameters predicted acceptable bioavailability properties with no indication of mutagenicity, tumorigenicity, irritability and reproductive effects. Oral absorption experiments using the human Caco-2 model showed high intestinal absorption of NSC745885 by passive transport mechanism with no intestinal efflux or active transport mechanisms. The unique molecular characterization as well as the illustrated anticancer spectra of activity and bioavailability properties warrant further development of our compounds and present a foundation brick in the pre-clinical investigations to implement such compounds in clinical practice.

AB - The novel compounds NSC745885 and NSC757963 developed at our laboratory were tested against a panel of 60 cancer cell lines at the National Cancer Institute, USA, and a panel of 39 cancer cell lines at the Japanese Foundation of Cancer Research. Both compounds demonstrated selective unique multi-log differential patterns of activity, with GI50 values in the sub-micro molar range against cancer cells rather than normal cardiac cells. NSC757963 showed high selectivity towards the leukemia subpanel. Activities of both compounds strongly correlated to expression of NFKB1 and CSNK2B genes, implying that they may inhibit the NF-κB pathway. Immunocytochemical microscopy of OVCAR-3 cells showed clear cytosolic accumulation of the NF-κB p65 subunit following treatment. Western blotting showed dose dependent inhibition of the nuclear expression of the NF-κB p65 subunit with subsequent accumulation in the cytosol following treatment. Docking experiments showed binding of both compounds to the NF-κB activator IKKβ subunit preventing its translocation to the nucleus. Collectively, these results confirm the ability of our compounds to inhibit the constitutively active NF-κB pathway of OVCAR-3 cells. Furthermore, COMPARE analysis indicated that the activity of NSC757963 is similar to the antituberculosis agent rifamycin SV, this was confirmed by testing the antimycobacterial activity of NSC757963 against Mycobacterium tuberculosis, results revealed potent activity suitable for use in clinical practice. Molecular properties and Lipinski's parameters predicted acceptable bioavailability properties with no indication of mutagenicity, tumorigenicity, irritability and reproductive effects. Oral absorption experiments using the human Caco-2 model showed high intestinal absorption of NSC745885 by passive transport mechanism with no intestinal efflux or active transport mechanisms. The unique molecular characterization as well as the illustrated anticancer spectra of activity and bioavailability properties warrant further development of our compounds and present a foundation brick in the pre-clinical investigations to implement such compounds in clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=84964687190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964687190&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0154278

DO - 10.1371/journal.pone.0154278

M3 - Article

C2 - 27100886

AN - SCOPUS:84964687190

VL - 11

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 4

M1 - e0154278

ER -